Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Parallel, Placebo-controlled study, to assess the safety, tolerability, and efficacy of PH Gastrilex (Amorphous calcium carbonate (ACC)) in the treatment of adult subjects with moderate to severe Crohn's Disease (Israeli Ministry of health study number: MOH_2023-05-01_012591).

Trial Profile

Randomized, Parallel, Placebo-controlled study, to assess the safety, tolerability, and efficacy of PH Gastrilex (Amorphous calcium carbonate (ACC)) in the treatment of adult subjects with moderate to severe Crohn's Disease (Israeli Ministry of health study number: MOH_2023-05-01_012591).

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMOR 1 (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 16 Dec 2025 Results presented in the Amorphical Media Release.
  • 24 Nov 2025 According to Amorphical Media Release, data is expected in Q3 of 2026.
  • 13 Nov 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top